Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Wahed FTSE USA Shariah ETF (HLAL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Wahed FTSE USA Shariah ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Wahed FTSE USA Shariah ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Wahed FTSE USA Shariah ETF trades at $72.96, while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). Which is the better fit depends on your goals.

HLALVRTX
Sector
Sector/ThematicHealth
52-Week High
$73.60$529.65
52-Week Low
$55.52$376.62
Market Cap
$134.25B
Enterprise Value
$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Wahed FTSE USA Shariah ETF

HLAL trades at $72.93, showing minimal daily movement with a slight 0.06% decline. Technical indicators present a mixed picture with bullish moving averages but neutral oscillators, while the stock lacks comprehensive fundamental data for traditional valuation metrics. The upcoming dividend of $0.02 per share scheduled for June 2026 provides a modest income component.

The stock's outlook remains uncertain due to limited financial disclosures. Investment opportunity hinges on future earnings visibility and market positioning, while primary risks include information gaps and market volatility. Further fundamental analysis requires updated SEC filings and earnings reports to assess true valuation potential.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.

Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.

Returns comparison

Trailing returns across standard periods

About Wahed FTSE USA Shariah ETF

HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.

Read more on HLAL

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX